Exploiting the promiscuity of imatinib

The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a 1.75 Å crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights into the binding specificit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Shun J, Wang, Jean YJ
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689438/
https://www.ncbi.nlm.nih.gov/pubmed/19435483
http://dx.doi.org/10.1186/jbiol134
Descripción
Sumario:The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a 1.75 Å crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights into the binding specificity and the off-target effects of the inhibitor.

Ejemplares similares